Revolution Medicines reported interim success in its Phase 3 RASolute 302 trial, with daraxonrasib nearly doubling survival versus standard chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. In the company’s readout, median overall survival was 13.2 months versus 6.7 months for chemotherapy, triggering an early end to the study at the interim checkpoint. Revolution said daraxonrasib also met progression-free survival endpoints at the interim analysis and plans to file with the FDA after finalization of the dataset. The company previously received an FDA “national priority” voucher pilot designation, which could accelerate review timelines after submission. The company’s approach targets a broader RAS biology question in pancreatic cancer by pursuing a RAS-family inhibitor strategy in a setting with historically poor outcomes, where new efficacy signals can be pivotal for regulatory strategy and subsequent trial design.